Clinical trial · Observational
Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab
Retrospective Analysis of Pyrotinib in the Treatment of HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260910-000001
Summary
Brief summary (as posted)
In China, pyrotinib is used for patients with HER2-positive advanced breast cancer who have progressed on trastuzumab. As anti-HER2 antibody therapy has advanced from trastuzumab monotherapy to trastuzumab-pertuzumab dual-target treatment, few clinical studies have investigated pyrotinib's efficacy among patients pre-treated with this dual-antibody regimen. This is a retrospective observational cohort study, which aims to assess the efficacy and safety of pyrotinib in this patient cohort.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pyrotinib 400mg | Drug | Pyrotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Pyrotinib
- description
- Pyrotinib-treated patients with prior trastuzumab and pertuzumab exposure
- interventionNames
- Drug: Pyrotinib 400mg
Primary outcomes (1)
- measure
- Progression free survival(PFS)
- timeFrame
- 4 years
- description
- PFS was defined as the time from the start of treatment to either the first documented disease progression or death from any cause
Secondary outcomes (1)
- measure
- Objective response rate (ORR)
- timeFrame
- 1year
- description
- ORR was defined as the proportion of patients with a complete response or a partial response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Diagnosis of unresectable locally advanced or metastatic breast cancer 2. Confirmed HER2-positive status, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with positive in situ hybridization (ISH) results 3. Prior systemic treatment of trastuzumab and pertuzumab 4. Adequate baseline cardiac, bone marrow, renal, hepatic, and blood coagulation functions 5. Life expectancy \> 3 months 6. ECOG ≤3 Exclusion Criteria: * 1\. Incomplete clinical case data
References
Publications (0)
Data not yet available